期刊
GYNECOLOGIC ONCOLOGY
卷 140, 期 3, 页码 537-544出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2015.12.011
关键词
Ovarian cancer; MK-0752; Cisplatin; Combination therapy
资金
- Chinese National Natural Science Foundation [31271444, 81201726, 81503293, 81373075]
- Specialized Research Fund for the Doctoral Program of Higher Education [20124401120007]
- Guangdong Natural Science Funds for Distinguished Young Scholar [2014A030306001]
- Science and Technology Program of Guangzhou [2014J4100009]
- Natural Science Foundation of Zhejiang Province, China [LQ12H16004]
Objective. Ovarian cancer is one of the most lethal of women cancers and lack potent therapeutic options. There have many evidences demonstrate the Notch signaling has deregulation in variety of human malignancies.MK-0752 is a novel potent gamma-secretase inhibitor and now assessed in clinical trial for treatment of several types of cancer, our objective was to investigate the anticancer effects and mechanisms of MK-0752 alone or combined with cisplatin in ovarian cancer. Methods. Cell lines used: A2780, OVCAR3, SKOV3, HO8910PM, the effects of MK-0752 and cisplatin on cell proliferation were measured by MTT assay. The effect of combination treatment was examined by isobologram analysis. The distribution of cell cycle and cell apoptosis were analyzed using PI and Annexin V-FITC/PI staining by flow cytometric analysis. The mechanism in biochemistry was analyzed by using Western blot. Mouse xenograft model of A2780 was established to observe the anti-ovarian cancer effects in vivo setting, nude mice were randomized into four groups (n = 6 per group) and treated every 4 days with control (solvent) group, MK-0752(25 mg/kg) group, cisplatin (2 mg/kg)group, combination group (both of MK-0752 and cisplatin). Results. MK-0752 alone actively induced cell growth inhibition, G2/M phase cell cycle arrest and apoptosis with down-regulation of Notch1 and its downstream effectors including Hes1, XIAP, c-Myc and MDM2 in a dose- and time-dependent manner. Moreover, sequential combination of cisplatin prior to MK-0752 significantly promoted cell apoptosis and inhibited the subcutaneous xenograft growth of ovarian cancer in nude mice. Conclusion. Our data supports the sequential combination of cisplatin prior to MK-0752 is a highly promising novel experimental therapeutic strategy against ovarian cancer. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据